Item 8.01. Other Events.
On November 8, 2022, Spero Therapeutics, Inc. issued a press release announcing
the closing of its previously announced exclusive license agreement with
GlaxoSmithKline Intellectual Property (No. 3) Limited for tebipenem HBr, an
investigational drug being developed as the first oral carbapenem antibiotic for
the treatment of complicated urinary tract infections, including pyelonephritis,
caused by certain bacteria. In connection with closing, pursuant to the license
agreement and a previously announced stock purchase agreement between the
parties, an affiliate of GSK has purchased 7,450,000 shares of the Company's
common stock at a purchase price of $1.20805 per share, resulting in gross
proceeds to the Company of approximately $9 million. A copy of the press release
is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
99.1 Press Release, dated November 8, 2022
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses